Body mass index and mortality in UK Biobank: revised estimates using Mendelian randomization Kaitlin H Wade ${ }^{1,2}$, David Carslake ${ }^{1,2}$, Naveed Sattar³, George Davey Smith ${ }^{1,2}$, Nicholas J Timpson ${ }^{1,2}$ ${ }^{1}$ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN
${ }^{2}$ Population Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, BS8 2BN
${ }^{3}$ Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA

## Corresponding author:

Dr Kaitlin H Wade

Oakfield House

Oakfield Road

Clifton
Bristol

BS8 2BN

Telephone: +44(0)1173314092
Email: kaitlin.wade@bristol.ac.uk

Running title: Mendelian randomization of BMI and mortality
Word count: 6516 (incl. introduction, methods, results, discussion and acknowledgments)

Funding: NJT is a Wellcome Trust Investigator (202802/Z/16/Z), a programme lead in the MRC Integrative Epidemiology Unit (MRC-IEU; MC_UU_12013/3), a work-package lead in the Integrative Cancer Epidemiology Programme (ICEP) that is supported by a Cancer Research UK programme grant (C18281/A19169) and works within the University of Bristol NIHR Biomedical Research Centre (BRC). GDS is the director and a programme lead in the MRC-IEU (MC_UU_12013/1). KHW is funded equally by two programs of the MRC-IEU (MC_UU_12013/3 and MC_UU_12013/4). DC is funded by the statistics theme of the MRC-IEU (MC_UU_12013/9) and is also affiliated to program 1 (MC_UU_12013/1). The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing of the report.

Disclosures: NS is a member of the UK Biobank international scientific advisory board and enhancements committee. This had no bearing on the study. Otherwise, the authors declared no conflicts of interest.

Author Contributions: All authors conceived and designed the study, interpreted results and approved the final manuscript. KHW had full access to all the data and performed all analyses with DC and takes responsibility for the integrity of the data and accuracy of the analysis. KHW, DC and NJT drafted the initial manuscript, the final version of which was critically appraised, revised and approved by all authors.

## Abstract

Objective: Obtain estimates of the causal relationship between different levels of body mass index (BMI) and mortality.

Methods: Mendelian randomization (MR) was conducted using genotypic variation reliably associated with BMI to test the causal effect of increasing BMI on all-cause and cause-specific mortality in participants of White British ancestry in UK Biobank.

Results: MR analyses supported existing evidence for a causal association between higher levels of BMI and greater risk of all-cause mortality (hazard ratio (HR) per $1 \mathrm{~kg} / \mathrm{m}^{2}: 1.02 ; 95 \% \mathrm{CI}: 0.97,1.06$ ) and mortality from cardiovascular diseases (HR: 1.12; 95\% CI: 1.02, 1.23), specifically coronary heart disease (HR: 1.19 ; $95 \%$ CI: $1.05,1.35$ ) and those other than stroke/aortic aneurysm (HR: 1.13; 95\% CI: 0.93 , 1.38), stomach cancer (HR: $1.30 ; 95 \%$ CI: $0.91,1.86$ ) and oesophageal cancer (HR: 1.08; 95\% CI: 0.84 , 1.38), and with decreased risk of lung cancer mortality (HR: $0.97 ; 95 \%$ CI: $0.84,1.11$ ). Sex-stratified analyses supported a causal role of higher BMI in increasing the risk of mortality from bladder cancer in males and other causes in females, but in decreasing the risk of respiratory disease mortality in males. The characteristic J-shaped observational association between BMI and mortality was visible with MR analyses but with a smaller value of BMI at which mortality risk was lowest and apparently flatter over a larger range of BMI.

Conclusion: Results support a causal role of higher BMI in increasing the risk of all-cause mortality and mortality from other causes. However, studies with greater numbers of deaths are needed to confirm the current findings.

Key words: Body mass index, mortality, Mendelian randomization, UK Biobank

## INTRODUCTION

Whilst severe obesity (a body mass index $[\mathrm{BMI}] \geq 35 \mathrm{~kg} / \mathrm{m}^{2}$ ) clearly increases the risk of death, having a BMI above $25 \mathrm{~kg} / \mathrm{m}^{2}$ has been shown to increase the risk of all-cause mortality and mortality specifically from vascular diseases, diabetes, respiratory diseases and neoplastic (cancer) in a doseresponse manner ${ }^{1-7}$. For example, each $5 \mathrm{~kg} / \mathrm{m}^{2}$ increase in BMI (or a transition between BMI categories for normal weight, overweight and obese, for example) has been shown to be associated with an increased risk of overall mortality by $>30 \%$, vascular mortality by $40 \%$ and the risk of diabetic, renal and hepatic mortality by $60-120 \%^{1,8}$. It was also estimated that $3.6 \%(N \sim 481,000)$ of all new adult cancer cases in 2012 (aged >30 after a 10-year lag period) were estimated to be attributable to high BMI, a quarter of which could be attributed to the rise in BMI since $1982^{9}$. Furthermore, having excess weight from early life over the lifecourse increases the risk of later mortality ${ }^{10-12}$.

However, there have been inconsistencies within the current literature relating to the "obesity paradox", whereby being overweight can appear seemingly protective ${ }^{13-16}$. Most prominently, in a systematic review and meta-analysis (providing a combined sample size of more than 2.88 million individuals), Flegal et al. showed a $\sim 6 \%$ lower risk of all-cause mortality in overweight individuals (i.e., a BMI of $25-30 \mathrm{~kg} / \mathrm{m}^{2}$ ) compared to normal weight individuals (i.e., a BMI of $18.5-25 \mathrm{~kg} / \mathrm{m}^{2}$ ) ${ }^{13}$. However, controversial findings like this are not without limitation, as confounding by age, ill-health and lifestyle factors plus selection bias (among other forms of bias) are likely ${ }^{17-19}$. Furthermore, many studies report a characteristic J-shaped curve in the association between BMI and the risk of mortality from varying causes $^{1,2,4,6,8,16, ~ 20-24}$. In this context, individuals at the lower tail of the BMI distribution (i.e., underweight or below $\sim 22.5-25 \mathrm{~kg} / \mathrm{m}^{2}$ ) have an increased risk of mortality along with those above the 'normal weight' threshold ${ }^{1,2,6,8}$. However, there are discrepancies in the reporting of this pattern, specifically between condition-specific mortality and populations of varying ancestries ${ }^{4,5,25-27}$.

Studies have used instrumental variable (IV) approaches to improve causal inference in the effect of exposures such as BMI, height and blood pressure (BP) on mortality using an intergenerational study design ${ }^{28-30}$. Using offspring exposures as IVs for the exposure of the parents in this context, whose mortality risk is being examined, provides a valid test as to whether an exposure (for example, BMI) has a causal effect on an outcome (for example, all-cause mortality) and allows the estimation of the magnitude of such an effect. Whilst this method has proved useful, there are caveats including, intergenerational
confounding between the instrument (offspring exposure) and outcome (parental mortality) may lead to biased causal estimates.

Mendelian randomization (MR) is a well-documented extension of IV methodology that uses genetic variants (most commonly, single nucleotide polymorphisms [SNPs]) as IVs to provide a relatively unbiased causal estimate of the effect of an exposure (here, BMI) on an outcome (here, mortality) ${ }^{31-34}$. The use of MR has provided evidence to support a causal effect of higher BMI increasing the risk of coronary heart disease (CHD), stroke, aortic aneurysm and type-2 diabetes ${ }^{35-39}$; cardiometabolic traits such as BP, fasting glucose and insulin, C-reactive protein, interleukin-6 and cholesterol levels ${ }^{40-42}$ and various types of cancer including oesophageal, ovarian, lung, stomach, kidney, endometrial and colorectal cancer ${ }^{43-52}$, whilst decreasing the risk of Parkinson disease ${ }^{53}$ and breast cancer ${ }^{43,54}$. However, there are inconsistencies within the field (for example, evidence suggesting no causal role of higher BMI in stroke ${ }^{55}$ or cancer risk ${ }^{56}$ ) and no study has explicitly used this technique to explore the causal role of BMI in allcause and cause-specific mortality. Here, data from the UK Biobank study, a powerful and large resource of comprehensive phenotypic, genetic and death registry data from the UK, were used to generate estimates of causal role of BMI in both all-cause and cause-specific mortality, avoiding many of the problems of confounding and bias seen elsewhere.

## METHODS

## The UK Biobank study

The UK Biobank study recruited over 500,000 people aged $37-73$ years ( $99.5 \%$ were between 40 and 69 years) from across the country in 2006-2010. Particularly focused on identifying determinants of human diseases in middle-aged and older individuals, participants provided a range of information (such as demographics, health status, lifestyle measures, cognitive testing, personality, self-report and physical/mental health measures) via questionnaires and interviews; anthropometric measures, BP readings and samples of blood, urine and saliva were taken. A full description of the study design, participants and quality control (QC) methods has been described in detail previously ${ }^{57-59}$. UK Biobank received ethical approval from the Research Ethics Committee (REC reference: 11/NW/0382)

Details of patient and public involvement in the UK Biobank are available online (www.ukbiobank.ac.uk/about-biobank-uk/ and https://www.ukbiobank.ac.uk/wp-content/uploads/2011/07/Summary-EGF-consultation.pdf?phpMyAdmin=trmKQIYdjj-nQIgj\%2CfAzikMhEnx6) and is available in a pre-print version ${ }^{58}$. No patients were specifically involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design or implementation of this study. No patients were asked to advise on the interpretation or writing up of the results. There are no specific plans to disseminate the results of the research to study participants, but the UK Biobank disseminates key findings from the projects on its websites. At the time of this study, phenotypic data were available for 502,619 participants.

## Measures of body mass index

Weight and height were collected at baseline when participants attended the initial assessment centre. Height (cm) was measured using a Seca 202 device in all participants in the UK Biobank along with sitting height. Weight ( kg ) was measured by a variety of means during the initial Assessment Centre visit, which was amalgamated into a single weight variable on the UK Biobank release data.

A total of 13 participants had a height measurement more than 4.56 standard deviations (SDs) away from the mean and one person had a sitting to standing height ratio of greater than 0.75 , which is not compatible with normal growth and development ${ }^{60}$. These participants were excluded, leaving 500,066 valid height measurements. Of these, 499,504 participants had weight measurements available (no weight values were excluded).

The UK Biobank currently has two different measures of adiposity - BMI calculated as weight divided by height squared $\left(\mathrm{kg} / \mathrm{m}^{2}\right)$ measured at the initial Assessment Centre visit and mass quantified using electrical impedance (in increments of 0.1 kg ), which was used to calculate a second measure of BMI. If BMI measured at the initial Assessment Centre visit was not available, the electrical impedance measure was used ( $\mathrm{n}=255$ ). Participants with substantial differences ( $>4.56 \mathrm{SD}$ ) between impedance and normal BMI measures were excluded ( $\mathrm{n}=1,164$ ), if both measures were available. After these preliminary steps, 498,595 participants had a valid BMI measurement (see Figure 1 for flow-chart of the participants used in this analysis).

## All-cause and cause-specific mortality

Data from death certificates were sent to UK Biobank on a quarterly basis provided by the National Health Service (NHS) Information Centre for participants from England and Wales and by NHS Central Register, Scotland for participants from Scotland. More detailed information on mortality are available at http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=115559. The death certificates include the disease or condition stated to be the underlying cause of death, as well as other conditions, diseases, injuries or events contributing to death but not related to the disease or condition causing it. Data were provided as date of death (DoD), an integer value for age of death (AoD) and underlying (primary) cause of death in International Classification of Diseases (ICD)-10 codes for all deaths that occurred between the $10 / 05 / 2006$ and $16 / 02 / 2016$. Rather than using the integer value of AoD from the death certificate, a more precise measure of AoD was derived by adding the time interval between date of initial assessment and DoD (in days) to the participant's age at initial assessment. All participants who were not recorded as dead by the $16^{\text {th }}$ of February 2016 were assumed to still be alive. The ICD-10 codes were categorised into all-cause and cause-specific mortality as presented in Table S1a. As of August 2017 (date of extraction for all data), there were 14,417 total deaths in the entire UK Biobank dataset (Table S1a), which remains to be the most updated data on mortality.

## Covariables

At the initial UK Biobank Assessment Centre, participants were given a touchscreen questionnaire, which included questions about sociodemographic status, early life, sex-specific factors, lifestyle and environment, family history, health and medical history and psychosocial factors. Of the
sociodemographic questions, participants were asked whether they had any of the following qualifications or equivalent: i) college or university degree, ii) A/AS-levels, iii) O-levels/GCSEs, iv) CSEs, v) NVQ or HND or HNC, vi) other professional qualifications eg. nursing or teaching, vii) none of the listed. Additionally, participants were asked which of the following described their current employment situation: i) in paid employment or self-employed, ii) retired, iii) looking after family home and/or family, iv) unable to work because of sickness or disability, v) unemployed, vi) doing unpaid or voluntary work, vii) full or part-time student, viii) none of the listed. Answers to these questions were used to derive variables the represented the participants' highest qualification level and current employment status, respectively.

Of the lifestyle and environment questions, participants were asked their smoking and alcohol drinking status, categorised into 'never', 'former or 'current'. Participants were also asked how many days in a typical week they would do 10 or more minutes of vigorous physical activity ("activities that make you sweat or breathe hard such as fast cycling, aerobic exercise and heavy lifting").

## Genotyping

Pre-imputation, QC, phasing and imputation of UK Biobank have been described elsewhere ${ }^{58,61}$. The genetic variants used were extracted genotypes from the UK Biobank imputation dataset (using only genetic variants imputed to the Haplotype Reference Consortium (HRC) reference panel), which had extensive QC performed including exclusion of the majority of third degree or closer relatives from a genetic kinship analysis of $96 \%$ of participants. For more details, see http://biobank.ctsu.ox.ac.uk. A total of 77 common genetic variants associated with BMI within people of only European ancestry (and excluding those that reached genome-wide levels of statistical confidence in only one sex or one stratum) in the most updated genome-wide association study (GWAS) conducted by the GIANT consortium (comprising up to 339,224 people) were extracted for MR analyses (Table S2) ${ }^{60,62}$. One SNP from the GWAS (rs12016871) was not present in the UK Biobank imputed genetic data, so a proxy SNP (i.e., one that is in linkage disequilibrium [LD] with rs12016871) was identified (rs4771122; $r^{2}=0.876$, distance $=2398 \mathrm{bp}$ ) and used in replacement ${ }^{62}$. We checked that each of the variants were imputed with high quality ( $>0.90$, Table S2).

The dosage of each genetic variant was weighted by its relative effect size on BMI obtained from the GIANT consortium ${ }^{62}$ and summed across all variants. The resulting total was then rescaled by dividing
by the sum of all effect sizes and multiplied by the number of genetic variants used. Therefore, this weighted genetic risk score (GRS) reflected the average number of BMI-increasing alleles each participant possessed ${ }^{60}$. In total, 487,409 participants had genetic data.

## Statistical analysis

As only the month and year of birth was available in the UK Biobank study, date of birth (DoB) was set as the $15^{\text {th }}$ of each month and year in which the participant was born. Participants were removed if they lacked information on date of birth (used for secular trends), initial assessment age and date, cause of death or AoD. Participants were also excluded if they lacked any/plausible information on DoD (i.e., if the individual had apparently died before the assessment clinic that they later attended). Participants who were never at risk during the follow-up period (i.e., who were recruited after $16^{\text {th }}$ February 2016) were also excluded.

The sample was restricted to UK Biobank participants of White British ancestry, defined by those who self-identified as "White British" and confirmed to have a similar genetic ancestry based on a principal components (PCs) analysis of the genome-wide genetic data ${ }^{58}$. Of those with full genetic data and information on BMI, 335,308 participants were included in analyses after recommended exclusions based on sex mismatch, sex-chromosome aneuploidy detection and related individuals (Supporting Methods, Figure 1). Of these, 9,570 had available data on cause, age and date of death (Table S1a, Figure 1).

Within the set of participants who had required information, Cox proportional hazards regression models were used to estimate conventional hazard ratios (HRs) for all-cause and causespecific mortality per unit increase $\left(\mathrm{kg} / \mathrm{m}^{2}\right)$ of BMI. The participant's age was used as a measure of time; thus, models were automatically adjusted for age. Analyses were conducted with the following two models: i) unadjusted and ii) adjusted for secular trends (DoB), current occupation, qualifications, smoking status, alcohol intake, physical activity and the first ten genetic PCs. Analyses were restricted to the conditions responsible a minimum number of deaths $(>40)^{29}$ and performed in the whole sample plus stratified by sex. The associations of the GRS with BMI and of each covariable with BMI and the GRS were tested using linear regression and associations of each covariable with all-cause mortality was assessed using Cox proportional hazards regression models, with all analyses adjusting for the first ten genetic PCs.

For MR analyses, a two-stage approach was conducted within the context of survival analyses. In the first stage, BMI was regressed on a GRS comprising 77 SNPs to generate the denominator of a twostage MR estimate. In the second stage, Cox proportional hazards models were used to estimate the HR of each mortality outcome with each unit increase in the GRS, thus generating the numerator for the twostage MR estimate. Exponentiating the ratio between the natural logarithm of the numerator (HR for each mortality outcome per unit increase in the GRS) and the denominator (association between BMI and the GRS) yielded a ratio MR estimate of the HR of each mortality outcome per unit increase ( $\mathrm{kg} / \mathrm{m}^{2}$ ) in BMI. Confidence intervals (CIs) were obtained using Taylor series expansions ${ }^{63}$. A simplification of the matrix method for the Durbin-Wu-Hausman (DWH) test for endogeneity was used to compare the HR estimates per unit increase in BMI derived from conventional Cox regression and the two-stage MR estimate (see Supporting Methods). All analyses were conducted using Stata 14.2.

## Linearity and proportional hazards assumption

To test the linearity of associations, fully-adjusted cubic spline models for both the exposure (here, BMI) and the instrument (here, the GRS) were plotted to show the pattern of association between levels of BMI and mortality. Observations were censored to restrict them to the period when death would have been recorded and used in the analysis. To focus on the densest part of the BMI distribution, the linearity tests were conducted after removing data below/above the $1^{\text {st }} / 99^{\text {th }}$ percentile, respectively, due to the scarcity of data towards the tails of the BMI distribution. In addition, an approximate MR analogue to the non-linear plot of mortality against BMI was obtained by estimating localized average causal effects (i.e., MR estimates of the log-linear effect of BMI on the hazard of mortality) within percentiles of the instrument-free exposure (set at the $5^{\text {th }}, 10^{\text {th }}, 25^{\text {th }}, 50^{\text {th }}, 75^{\text {th }}$ and $85^{\text {th }}$ percentile) ${ }^{64}$. These localised average causal effects were then joined together and plotted against corresponding quantiles of the original exposure ${ }^{65}$. HRs were calculated relative to the mean BMI of $27 \mathrm{~kg} / \mathrm{m}^{2}$ and 1000 bootstrap resamples were used to obtain CIs. Meta-regression was used to test for a linear trend in association between the GRS and BMI (i.e. denominator of the two-stage MR estimate) over quantiles of the instrument-free exposure.

To check the proportional hazards assumption, the Schoenfeld residuals for BMI from the cubic spline models of each mortality outcome were tested for association with the natural log of the follow-up time (here, age) using both conventional Cox regression and MR analysis. If there was evidence for a
difference in the association between BMI and the risk of mortality with age (i.e., a Bonferroni-corrected P-value of $0.05 / 138$ tests $=0.0004)$, an interaction term was fitted to the cubic spline model using the "tvc()" option for survival analyses in Stata.

## Sensitivity analyses

To investigate the validity of the GRS as an IV within this context, MR-Egger was used to detect and accommodate violations of the MR assumptions, specifically horizontal pleiotropy ${ }^{66}$. The intercept obtained from the MR-Egger test is used as an indication of pleiotropy and the slope can be considered as the estimate of the causal effect between the exposure (here, BMI) and the outcome (here, all-cause and cause-specific mortality). In addition, the weighted median- and mode-based methods were used ${ }^{67,68,}$ which vary in their assumptions of instrument validity. The weighted median approach provides a causal estimate even when $50 \%$ of instruments are invalid and the weighted mode estimate is consistent when the largest number of similar causal effect estimates comes from valid instruments, even if most instruments are invalid. MR-Egger, weighted median and weighted mode estimates were compared to those obtained from the inverse-variance weighted (IVW) for two-sample MR ${ }^{66}$. For these analyses, the first-stage estimates (coefficients of the association between each SNP and BMI) were obtained from an independent external source, as to not induce weak instrument bias ${ }^{69,70}$, and the second-stage estimates (natural logarithm of the HR for each mortality outcome with each SNP) were obtained directly from UK Biobank.

In the UK Biobank sample, there is evidence to suggest a differential array effect on markers scattered across the genome (i.e., those that were genotyped using the Affymetrix UK Biobank Axiom® Array or the Affymetrix UK BiLEVE Axiom Array ${ }^{58,61}$ ) and the UK BiLEVE sub-sample, which included >50,000 participants and used the UK BiLEVE Axiom Array, also preferentially selected individuals based on smoking intensity. To evaluate the impact of this differential array effect, MR sensitivity analyses were conducted with an additional adjustment of genotyping chip.

As a final sensitivity analysis, the GRS was restricted to exclude the genetic variants known to be classified as having a secondary signal within a locus to other phenotypes ( $\mathrm{N}=7$; leaving 70 in the GRS, Table S3) ${ }^{37,60}$ and all MR analyses were repeated.

## RESULTS

Of those included, the average age of initial assessment was 56.9 years old (SD=8) and participants had an average BMI of $27.4 \mathrm{~kg} / \mathrm{m}^{2}(\mathrm{SD}=4.7)$ (Table 1). Of the 335,308 participants with required information for mortality analyses, 9,570 participants ( $\mathrm{N}=5,882 / 3,688$ males/females, respectively) had died by the $16^{\text {th }}$ of February 2016 at an average age of 65.7 years old (SD=6.9). Most had died from various types of cardiovascular diseases (CVDs) and cancer (Table S1a/1b for wholesample and sex-specific mortality).

## Observational analyses

In unadjusted observational analyses, higher BMI was associated with a higher risk of all-cause mortality and mortality from CVD, specifically CHD and those other than stroke and aortic aneurysm, overall cancer and cancer in the stomach, oesophagus, kidney and liver (Table 2). Higher BMI was also associated with a lower risk of lung cancer mortality.

Adjusting Cox regression models for covariables made little difference to results, providing evidence that BMI was associated with a higher risk of all-cause mortality (HR per $1 \mathrm{~kg} / \mathrm{m}^{2}$ higher BMI: 1.02; 95\% CI: 1.01, 1.02; $P=9.72 \times 10^{-11}$ ) and mortality from CVD (HR: $1.07 ; 95 \% \mathrm{CI}: 1.06,1.08 ; P=2.12 \times 10^{-}$ ${ }^{34}$ ), specifically CHD (HR: $1.08 ; 95 \%$ CI: $1.06,1.09 ; P=2.22 \times 10^{-22}$ ) and those other than stroke and aortic aneurysm (HR: 1.10; 95\% CI: 1.08, 1.13; $P=6.66 \times 10^{-22}$ ), as well as a higher risk of mortality from overall cancer (HR: 1.01; 95\% CI: 1.00, 1.01; $P=0.03$ ) and cancer of the kidney (HR: $1.07 ; 95 \% \mathrm{CI}: 1.03,1.11$; $P=1.40 \times 10^{-04}$ ) and liver (HR: $1.05 ; 95 \%$ CI: 1.01, $1.09 ; P=0.01$ ) (Table 2). The inverse association between BMI and risk of lung cancer also remained consistent after adjusting for covariables (HR: 0.97; 95\% CI: $0.95,0.99 ; P=0.004$ ) and there was evidence for an inverse association between BMI and mortality from external causes (HR: 0.96; 95\% CI: 0.94, $0.99 ; P=0.02$ ). The association between BMI and risk of mortality from stomach cancer slightly attenuated (HR: 1.04; 95\% CI: 1.00, 1.09; $P=0.06$ ) and, whilst the estimate of association between BMI and risk of mortality from oesophageal cancer remained consistent (HR: 1.03; 95\% CI: 0.99, 1.06; $P=0.11$ ), CIs widened after adjustment (Table 2).

Results were similar within sex-stratified analyses, with additional evidence for an association between higher BMI and decreased risk of mortality from respiratory disease in males (HR: $0.91 ; 95 \% \mathrm{CI}$ : $0.88,0.95 ; P=2.28 \times 10^{-06}$ ) but an increased risk of mortality from respiratory disease in females (HR: 1.06; $95 \%$ CI: 1.02, $1.09 ; P=0.002$ ), which was not present in the overall sample (Table 3 and Table 4 for males
and females, respectively). In males, adjusted Cox regression analyses also provided evidence for an association between higher BMI and increased risk of prostate cancer mortality (HR: 1.05; 95\% CI: 1.02, 1.08; $P=0.003$ ), alongside greater magnitudes of association of higher BMI with a decreased risk of mortality from lung cancer (HR: $0.94 ; 95 \%$ CI: $0.91,0.97 ; P=3.54 \times 10^{-05}$ ) and bladder cancer (HR: 0.93 ; $95 \%$ CI: $0.87,1.00 ; P=0.06$ ), and increased risk of mortality from oesophageal cancer (HR: 1.07; 95\% CI: $1.04,1.11 ; P=8.50 \times 10^{-05}$ ) and liver cancer (HR: $1.08 ; 95 \% \mathrm{CI}: 1.03,1.13 ; P=0.003$ ). The estimate of association between higher BMI and mortality from external causes was smaller compared to that in the whole sample (HR: $0.97 ; 95 \%$ CI: $0.93,1.01 ; P=0.11$ ); however, all CIs overlapped (Table 3).

In females, adjusted Cox regression analyses provided evidence for an association between higher BMI and increased risk of mortality from endometrial cancer (HR: 1.12; 95\% CI: 1.07, 1.18; $P=1.29 \times 10^{-05}$ ), weak evidence for an association of higher BMI with an increased risk of mortality from post-menopausal breast cancer (HR: 1.02; 95\% CI: 1.00, 1.04; $P=0.13$ ) and other causes (HR: 1.02; 95\% CI: 1.00, 1.04; $P=0.09$ ). There was no strong evidence of an association with ovarian cancer (Table 4). There was no strong evidence of an association of BMI with mortality from lung cancer and the estimate of association between higher BMI and mortality from oesophageal cancer was in the opposite direction to that observed in the whole sample (HR: $0.87 ; 95 \%$ CI: $0.80,0.95 ; P=0.001$ ); however, all CIs overlapped (Table 4).

Association between the GRS and BMI
Each unit increase in the GRS (comprising 77 SNPs) in the UK Biobank participants of White British ancestry was associated with $0.11 \mathrm{~kg} / \mathrm{m}^{2}$ higher BMI (95\% CI: $0.11,0.11 ; P<1.20 \times 10^{-307}$ ), explaining $1.8 \%$ of the variance in UK Biobank and was similar between males and females (Table 5).

## Confounder analysis

As expected with observational analyses, both BMI and mortality were associated with all covariables including age of initial assessment, sex, smoking status, alcohol consumption, qualifications, employment status and physical activity (Table S4 and 5 for BMI and all-cause mortality, respectively). Unlike the direct measurement of BMI, the GRS was associated with covariables to a much lesser extent, with all estimates near zero (Table S6).

## MR analyses

Within the whole UK Biobank sample, using the GRS as an IV in MR analyses provided estimates of a similar or greater magnitude to observational analyses (albeit, with wider CIs), supporting the causal role of higher BMI in increasing the risk of all-cause mortality (HR: 1.02; 95\% CI: $0.97,1.06 ; P=0.45$ ) and mortality from CVD (HR: $1.12 ; 95 \%$ CI: $1.02,1.23 ; P=0.02$ ), specifically CHD (HR: $1.19 ; 95 \% \mathrm{CI}: 1.05,1.35 ;$ $P=0.01$ ) and those other than stroke and aortic aneurysm (HR: 1.13; 95\% CI: $0.93,1.38 ; P=0.22$ ), as well as mortality from stomach cancer (HR: $1.30 ; 95 \% \mathrm{CI}: 0.91,1.86 ; P=0.16$ ) and oesophageal cancer (HR: $1.08 ; 95 \%$ CI: $0.84,1.38 ; P=0.55$ ) (Table 2). Although CIs were wide, the estimate of the effect of higher BMI on decreasing the risk of mortality from lung cancer was consistent to that obtained in observational analyses (HR: $0.97 ; 95 \% \mathrm{CI}: 0.84,1.11 ; P=0.63$ ). There was also evidence supporting the causal role of higher BMI in increasing the risk of mortality from external causes (HR: 1.35; 95\% CI: 1.09, 1.67; P=0.01), unlike the inverse association obtained in observational analyses (DWH $P$-value for comparison between observational and MR analyses: 0.002). In contrast, the estimates of the effect of higher BMI on mortality from cancer, kidney cancer and liver cancer were attenuated or in the opposite direction, with CIs too wide for comparison to observational analyses or conclusive interpretation (Table 2).

Results for males were similar, in that the estimates of the causal role of higher BMI in increasing the risk of all-cause mortality and mortality from CVDs (including CHD and those other than stroke and aortic aneurysm), stomach cancer, oesophageal cancer and kidney cancer, as well as the decreased risk of mortality from respiratory diseases, lung cancer and bladder cancer, were consistent to or greater than the observational analyses (Table 3). The estimates of the effect of higher BMI on risk of mortality from prostate cancer (HR: $0.73 ; 95 \%$ CI: $0.57,0.93 ; P=0.01$ ) and external causes (HR: $1.25 ; 95 \%$ CI: $0.94,1.67$; $P=0.13$ ) were in the opposite direction to those obtained in observational analyses (DWH $P$-value for comparison: 0.004 and 0.08 , respectively). The estimates of the effect of higher BMI on mortality from cancer and liver cancer were attenuated or in the opposite direction, with CIs too wide for comparison to observational analyses or conclusive interpretation (Table 3).

In females, the estimates of the effect of higher BMI on increasing the risk of mortality from CVDs (including CHD and those other than stroke) and other causes, as well as the decreased risk of mortality from oesophageal cancer, were consistent to the observational analyses (Table 4). The estimates of the effect of higher BMI on risk of mortality from external causes (HR: $1.56 ; 95 \%$ CI: $1.10,2.20 ; P=0.01$ ), breast cancer (HR: $0.87 ; 95 \%$ CI: $0.73,1.02 ; P=0.09$ ), specifically post-menopausal breast cancer (HR:
0.87 ; $95 \%$ CI: $0.73,1.04 ; P=0.14$ ), and endometrial cancer (HR: $0.71 ; 95 \% \mathrm{CI}: 0.41,1.23 ; P=0.23$ ) were in the opposite direction to those obtained in observational analyses (DWH $P$-value for comparison: 0.01 , $0.06,0.09$ and 0.10 , respectively). Furthermore, the estimates of the effect of higher BMI on mortality from all causes, respiratory diseases, overall cancer and kidney cancer were attenuated or in the opposite direction compared to observational analyses, but with CIs too wide for conclusive interpretation (Table 4).

## Linearity and proportional hazards assumption

The pattern of association between the GRS and all-cause mortality appeared linear (Figure 2); however, the CIs were wide. Assessment of linearity between BMI and most causes of mortality showed a J-shaped association in observational analyses (Figure 3A). When localised average causal effects within strata of instrument-free BMI were used to plot an approximate MR analogue to the plot of mortality against BMI, a J-shape was visible (Figure 3B), but with a smaller value of BMI at which mortality risk was lowest ( $\sim 23 \mathrm{~kg} / \mathrm{m}^{2}$ compared to $\sim 26 \mathrm{~kg} / \mathrm{m}^{2}$ with observational analyses) and apparently flatter over a larger range of BMI, as compared to the observational association. However, CIs were wide with this analysis. Meta-regression testing for a linear trend in the association between the GRS and BMI over quantiles of instrument-free exposure provided some evidence that the GRS-BMI association was nonlinear ( $P$-value for linear trend $=0.07$ and $P$-value for heterogeneity $<0.001$ ). This was primarily driven by the extreme quantiles of BMI, as removal of these quantiles indicated a linear association in the metaregression $(P$-value for linear trend $=0.99$ and $P$-value for heterogeneity $<0.001$ ).

The proportional hazards assumption held for all causes of mortality in both the conventional Cox regression and the MR analyses, especially given the number of tests being performed (Table S7a and S7b for correlation coefficients and corresponding $P$-values for testing the proportional hazards assumption in observational and MR analyses, respectively).

## Sensitivity analyses

Across all methods applied, which assume linearity (including MR-Egger, weighted median- and mode-based estimators as compared to the IVW approach), MR-derived estimates were consistent (Table S8a, S8b and S8c for results in the whole sample, males and females, respectively). Whilst there was no evidence for pleiotropic effects in the estimation of the causal role of BMI in a majority of the mortality
causes, the intercept estimate from MR-Egger regression showed marginal evidence for pleiotropy in the association between BMI and mortality from other cancers (intercept: $0.96 ; 95 \%$ CI: $0.93,1.00 ; P=0.03$; HR from MR-Egger regression: 1.25; 95\% CI: $0.96,1.62 ; P=0.09$, Table S8a and Figure S1a) and mortality from other causes (intercept: 0.97; 95\% CI: 0.94, 0.99; $P=0.02$; HR from MR-Egger regression: 1.27; 95\% CI: 1.03, 1.58; $P=0.03$, Figure $S 1 b$ ), suggesting an underestimated $M R$ estimate with negative directional pleiotropy. In males, there was marginal evidence for pleiotropy in the association between BMI and mortality from other cancers (intercept: $0.95 ; 95 \% \mathrm{CI}: 0.91,0.99 ; P=0.01 ;$ HR from MR-Egger regression: 1.35; 95\% CI: 0.97, 1.89; P=0.07, Table S8b and Figure S2a) and other causes (intercept: 0.96; 95\% CI: 0.93 , 1.00; $P=0.04$; HR from MR-Egger regression: 1.27; 95\% CI: $0.97,1.66 ; P=0.08$, Figure S2b), similarly suggesting negative directional pleiotropy. There was no strong evidence of directional pleiotropy in female-specific analyses (Table S8c). In both the whole sample and male-specific analyses, the negative directional pleiotropy was likely driven by the rs17024393 SNP (in the association between BMI and mortality from other cancers) and by many SNPs with small positive effects on BMI and small negative effects on mortality (in the association between BMI and mortality from other causes).

Additional adjustment of genotyping chip made no substantive difference to the current MR analyses (Table S9), providing no strong evidence of a differential array effect. When limiting the GRS to exclude the SNPs that may have potentially pleiotropic effects based on previous literature and biological plausibility $(\mathrm{N}=70)$, there was no substantive difference in the association between the GRS and BMI (Table S10). The results of the MR analyses were similar to the main analyses (Table S11).

## DISCUSSION

Results supported the causal role of higher BMI in increasing the risk of all-cause mortality and mortality specifically from CVD (including CHD and those other than stroke and aortic aneurysm) plus various cancer sub-types including those of the oesophagus and stomach, as well as decreasing the risk of lung cancer mortality. Sex-stratified analyses were consistent to those in the whole sample and provided additional evidence to support the causal role of higher BMI in increasing the risk of mortality from bladder cancer in males and other causes in females, whilst decreasing the risk of mortality from respiratory diseases in males.

The current results for the most common mortality causes are consistent with previous studies that support the causal role of higher BMI in increasing the risk of all-cause mortality and mortality specifically from vascular diseases and various cancers, whilst decreasing the risk of lung cancer mortality ${ }^{1,2,5,7,8,21}$. For example, the largest systematic review and meta-analysis of this relationship (including more than 30 million participants and approximately 3.7 million deaths) showed consistent evidence that each $5 \mathrm{~kg} / \mathrm{m}^{2}$ increment in BMI was associated with a $5 \%$ increased risk (95\% CI: 4-7\%) of all-cause mortality in all participants ${ }^{21}$. Concordant with this, scaling the current results in UK Biobank suggested that each $5 \mathrm{~kg} / \mathrm{m}^{2}$ increase in BMI was associated with a $\sim 10 \%$ increased risk in all-cause mortality. Similarly, and consistent with a collaborative analysis of over 900,000 adults showing an approximate $40 \%$ increased risk of vascular mortality with each $5 \mathrm{~kg} / \mathrm{m}^{2}$ higher BMI ${ }^{1}$, scaling the current results to reflect the same increase in BMI implied a $\sim 75 \%$ increased risk of overall CVD and, specifically, more than a 2.5 -fold increased risk of CHD.

For cancer, whilst CIs for all MR analyses were wide, the current analyses provided evidence for a causal role of higher BMI increasing the risk of mortality from cancer of the stomach and oesophagus, whilst decreasing the risk of lung cancer mortality in all participants (but CIs were wide). Sex-specific analyses were broadly consistent with an additional inverse association with mortality from respiratory diseases and bladder cancer in males, in whom the effect on kidney cancer mortality was also stronger than in all participants. In females, there was consistent evidence that BMI played a causal role in mortality from other causes. However, these analyses were likely limited by the rarity of mortality from cancer (i.e., many cancers had fewer than 300 cases), accentuated further particularly in analyses within female participants, where many estimates derived from MR analyses were opposite to those from observational analyses or had CIs too wide for interpretation. Despite this, many effect estimates were in
the same direction as those derived from previous large-scale meta-analyses and reviews. The association of BMI on incidence of 22 cancer sites in 5.24 million individuals, suggested linear positive relationships with cancers of the kidney, liver, colorectal and ovary and inverse associations with prostate, premenopausal breast cancer and lung cancer, the latter being strongly driven by smoking status ${ }^{25}$. Consistent with this, despite estimates from the conventional Cox regression suggesting a positive association between BMI and prostate cancer mortality in UK Biobank, MR analyses provided evidence in the opposite direction (i.e., higher BMI reducing prostate risk). Additionally, in the Million Women Study, incrementally higher BMI was associated with a higher risk of mortality from cancers of the endometrium, oesophagus (specifically, adenocarcinoma subtypes), kidney, pancreas, lymphatic system, ovary, breast cancer (in post-menopausal women) and colorectal cancer (in pre-menopausal women) ${ }^{5}$. However, whilst there was observational evidence for a positive effect on mortality from endometrial cancer and post-menopausal breast cancer, estimates were inverse in MR analyses.

When using instrument-free BMI as the exposure, the association between BMI and all-cause mortality showed a J-shaped pattern but appeared flatter over a larger range of BMI, as compared to the observational association, with a smaller value of BMI at which mortality risk was lowest. Such a difference may be suggestive of confounding in observational associations (i.e., potentially overestimating the harmful effects of underweight whilst underestimating the harmful effects of being overweight and obese); however, we accept wide CIs suggest a need for more power to be conclusive. Likely explanations for a heightened J-shaped curve in observational studies include confounding by lifestyle factors, which may generate a higher risk of mortality in underweight individuals, or reverse causality. Many previous studies used populations comprising older individuals with likely existing illnesses, which may generate a spurious association of lower BMI increasing the risk of mortality (i.e., those who lose weight as a result of disease) ${ }^{17,28,29}$. Indeed, in the largest study to date, overestimation of estimates and this characteristic J-shaped association were reported greatest in analyses with the most potential for bias (including all participants, current, former or never smokers and studies with short follow-up durations of < 5 years), highlighting the importance for unbiased modes of estimation (such as those used in the current analysis) ${ }^{21}$. Those that attempt to appropriately control for such effects (such as adjusting for baseline traits, restricting analyses to individuals who never smoked or had a longer follow-up), observe an emerging linear association ${ }^{2,11,21,71,72}$, suggesting an underestimation of the positive link of BMI on mortality but falsely overestimating the effect of low BMI on mortality in a general population. Whilst it is
plausible that individuals considered severely and unhealthily underweight have a higher risk of mortality than those within the normal ranges of $\mathrm{BMI}^{73}$, the current findings in this large population of healthy individuals support a more linear association, with lower BMI being protective. Furthermore, the lowest risk of mortality occurred at approximately $23 \mathrm{~kg} / \mathrm{m}^{2}$ when using MR methodology, as opposed to being overweight (i.e., a BMI of $25-30 \mathrm{~kg} / \mathrm{m}^{2}$ ), which was observed in the current observational analyses and has been implied previously by some of the existing observational literature ${ }^{13}$. Therefore, a stable BMI within the 'normal' range (i.e., $18.5-25 \mathrm{~kg} / \mathrm{m}^{2}$ ) may be the most beneficially healthy with regards to reducing mortality risk, with any reduction within that range likely to be beneficial ${ }^{8,21}$.

Use of the UK Biobank study has enabled an MR investigation of the causal role of BMI in allcause and cause-specific mortality. This has been afforded given the large sample size, comprehensive genetic and phenotypic measurements and detailed death registry information. Whilst the power to detect associations with MR analyses was low for many mortality causes in the current study, given the incidence of the outcomes tested, this will increase in the coming years where incidence and mortality from many causes will approximately double by $2022^{57}$.

The MR concept rests on several key assumptions ${ }^{31-34}$ : (i) the IV (here, the GRS) must be associated with the exposure (here, BMI); (ii) the IV must be independent of the factors that act as confounders of the association between the exposure and the outcome (here, all-cause and cause-specific mortality); and (iii) there must be no independent pathway between the IV and outcome other than through the exposure - horizontal pleiotropy ${ }^{34}$. These assumptions were tested where possible, but it can be difficult to directly assess whether possible sources of pleiotropy are horizontal (independent of the exposure) or vertical (involved in the causal pathway between the exposure and outcome) ${ }^{66}$. Within the context of the current study, sensitivity analyses conducted provided little evidence of pleiotropy in MR estimates and awarded greater confidence in the validity of the instrument used and, thus, MR-derived estimates. Reverse causality is an important source of bias in observational estimates of the association between BMI and mortality and may be the driver of the characteristic J-shaped association. However whilst it is possible that mortality from specific causes can influence the relative distribution of genetic variants within a selected sample ${ }^{74}$, it is likely that this potential bias is less marked than that seen in observational studies (especially in light of the use of common genetic variants to predict a complex risk factor like BMI).

The UK Biobank study is comprised of relatively healthy volunteer participants and is a unique opportunity to undertake these analyses. Even in this study, however, the sample sizes available were limited. With this, it is likely that participants with higher education and socioeconomic position and different causes of death and estimates of association may not be representative of and generalisable to the wider national or international populations. Furthermore, to remove any possible effect of genetic confounding, the current analyses were restricted to those only of White British ancestry, limiting the generalisability of results to other ancestral groups. Generally, the current analyses were likely limited by the rarity of many mortality causes (e.g., the number of individuals who had died from diabetes and other cardiovascular-related traits were insufficient to include), accentuated further in sex-stratified analyses. Therefore, the potential role of chance and low statistical power in many relatively weak associations such as those observed between BMI and mortality from the various rare mortality causes cannot be ruled out.

## Conclusions

This study represents the application of MR to assess the causal effect of higher BMI on the risk and cause of mortality. Results supported the causal role of higher BMI in increasing the risk of all-cause mortality and mortality specifically from CVD, various cancers and other causes. Along with the comprehensive studies with greater numbers of deaths in combination with the application of robust causal inference methods such as those employed here that appropriately account for the heavy burden of confounding, reverse causation and bias within observational epidemiological designs, our results further highlight the need for a global effort to reduce the rising population trends for excess weight from an early age.

## Acknowledgements

The authors are grateful to the UK Biobank participants. This research has been conducted using the UK Biobank Resource under the Application Number 16391.

## References

1. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.
2. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-Mass Index and Mortality among 1.46 Million White Adults. New England Journal of Medicine. 2010;363:2211-2219.
3. Parr CL, Batty GD, Lam TH, et al. Obesity, overweight and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424519 participants. The Lancet Oncology. 2010;11:741752.
4. Chen Y, Copeland WK, Vedanthan R, et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ : British Medical Journal. 2013;347.
5. Reeves GK, Pirie K, Beral V, Green J, Spencer E and Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134.
6. Zheng W, McLerran DF, Rolland B, et al. Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians. New England Journal of Medicine. 2011;364:719-729.
7. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356.
8. The Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (London, England). 2016;388:776-786.
9. Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. The Lancet Oncology. 2015;16:36-46.
10. von Bonsdorff MB, Törmäkangas T, Rantanen T, et al. Early life body mass trajectories and mortality in older age: Findings from the Helsinki Birth Cohort Study. Annals of Medicine. 2015;47:34-39.
11. Twig G, Yaniv G, Levine H, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. New England Journal of Medicine. 2016;374:2430-2440.
12. Hirko KA, Kantor ED, Cohen SS, Blot WJ, Stampfer MJ and Signorello LB. Body Mass Index in Young Adulthood, Obesity Trajectory, and Premature Mortality. American Journal of Epidemiology. 2015;182:441450.
13. Flegal KM, Kit BK, Orpana H and Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. JAMA. 2013;309:71-82.
14. Wang J-B, Gu M-J, Shen P, et al. Body Mass Index and Mortality: A 10-Year Prospective Study in China. Scientific Reports. 2016;6:31609.
15. Yi S-W, Ohrr H, Shin S-A and Yi J-J. Sex-age-specific association of body mass index with all-cause mortality among 12.8 million Korean adults: a prospective cohort study. International Journal of Epidemiology. 2015;44:1696-1705.
16. Lee J, Meyerhardt JA, Giovannucci E and Jeon JY. Association between Body Mass Index and Prognosis of Colorectal Cancer: A Meta-Analysis of Prospective Cohort Studies. PLoS ONE. 2015;10:e0120706.
17. Willett WC, Hu FB and Thun M. Overweight, obesity, and all-cause mortality.JAMA. 2013;309:16811682.
18. Ramos-Esquivel A. Overweight, obesity, and all-cause mortality. JAMA. 2013;309:1680-1680.
19. Bhupathiraju SN, Di Angelantonio E, Danesh J and Hu FB. Commentary on "A meta-analysis but not a systematic review: an evaluation of the Global BMI Mortality Collaboration". Journal of Clinical Epidemiology.
20. Jackson CL, Yeh H-C, Szklo M, Hu FB, Wang N-Y, Dray-Spira R and Brancati FL. Body-Mass Index and All-Cause Mortality in US Adults With and Without Diabetes. Journal of General Internal Medicine. 2014;29:25-33.
21. Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear doseresponse meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353.
22. Aune D, Sen A, Norat T, et al. Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. Circulation. 2016;133:639.
23. Padwal R, Leslie WD, Lix LM and Majumdar SR. Relationship among body fat percentage, body mass index, and all-cause mortality: A cohort study. Annals of Internal Medicine. 2016;164:532-541.
24. Afzal S, Tybjærg-Hansen A, Jensen GB and Nordestgaard BG. Change in body mass index associated with lowest mortality in denmark, 1976-2013. JAMA. 2016;315:1989-1996.
25. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA and Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. The Lancet. 2014;384:755-765.
26. Secord AA, Hasselblad V, Von Gruenigen VE, et al. Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. Gynecologic Oncology. 2016;140:184-190.
27. Jiang Wubin CB. Does body mass index correlate with mortality of prostate cancer? A doseresponse meta-analysis of cohort studies. . International Journal of Clinical and Experimental Medicine. 2017;10:88-96
28. Davey Smith G, Sterne JA, Fraser A, Tynelius P, Lawlor DA and Rasmussen F. The association between BMI and mortality using offspring BMI as an indicator of own BMI: large intergenerational mortality study. BMJ. 2009;339.
29. Wade KH, Carslake D, Ivar Nilsen T, Timpson NJ, Davey Smith G and Romundstad P. Blood pressure and mortality: using offspring blood pressure as an instrument for own blood pressure in the HUNT study. Scientific Reports. 2015;5:12399.
30. Carslake D, Fraser A, Davey Smith G, et al. Associations of mortality with own height using son's height as an instrumental variable. Economics and Human Biology. 2013;11:351-359.
31. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epi. 2004;33:30-42.
32. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiology studies. Hum Mol Genet. 2014.
33. Davey Smith G, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med. 2008;40:524-541
34. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C and Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. The American Journal of Clinical Nutrition. 2016.
35. Dale CE, Fatemifar G, Palmer TM, et al. Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. Circulation. 2017;135:2373.
36. Hägg S, Fall T, Ploner A, et al. Adiposity as a cause of cardiovascular disease: a Mendelian randomization study. International Journal of Epidemiology. 2015;44:578-586.
37. Corbin LJ, Richmond RC, Wade KH, et al. BMI as a Modifiable Risk Factor for Type 2 Diabetes: Refining and Understanding Causal Estimates Using Mendelian Randomization. Diabetes. 2016;65:30023007.
38. Nordestgaard BG, Palmer TM, Benn M, et al. The Effect of Elevated Body Mass Index on Ischemic Heart Disease Risk: Causal Estimates from a Mendelian Randomisation Approach. PLOS Medicine. 2012;9:e1001212.
39. van 't Hof FN, Vaucher J, Holmes MV, et al. Genetic variants associated with type 2 diabetes and adiposity and risk of intracranial and abdominal aortic aneurysms. Eur J Hum Genet. 2017;25:758-762.
40. Fall T, Hägg S, Ploner A, et al. Age- and Sex-Specific Causal Effects of Adiposity on Cardiovascular Risk Factors. Diabetes. 2015;64:1841-1852.
41. Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjærg-Hansen A and Nordestgaard BG. Does Greater Adiposity Increase Blood Pressure and Hypertension Risk? Hypertension. 2009;54:84.
42. Holmes MV, Lange LA, Palmer T, L et al. Causal Effects of Body Mass Index on Cardiometabolic Traits and Events: A Mendelian Randomization Analysis. American Journal of Human Genetics. 2014;94:198-208.
43. Gao C, Patel CJ, Michailidou K, et al P. Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. International Journal of Epidemiology. 2016;45:896-908.
44. Jarvis D, Mitchell JS, Law PJ, et al. Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. British Journal of Cancer. 2016;115:266-272.
45. Thrift AP, Gong J, Peters U, et al. Mendelian randomization study of body mass index and colorectal cancer risk. Cancer epidemiology, biomarkers \& prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015;24:1024-1031.
46. Brennan P, McKay J, Moore L, et al. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. International Journal of Epidemiology. 2009;38:971-975.
47. Painter JN, O'Mara TA, Marquart L, et al. Genetic risk score Mendelian randomization shows obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer. Cancer
epidemiology, biomarkers \& prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016;25:1503-1510.
48. Nead KT, Sharp SJ, Thompson DJ, et al. Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis. JNCI Journal of the National Cancer Institute. 2015;107:djv178.
49. Mao Y, Yan C, Lu Q, et al. Genetically predicted high body mass index is associated with increased gastric cancer risk. Eur J Hum Genet. 2017;25:1061-1066.
50. Thrift AP, Shaheen NJ, Gammon MD, et al. Obesity and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: A Mendelian Randomization Study. JNCI Journal of the National Cancer Institute. 2014;106:dju252.
51. Dixon SC, Nagle CM, Thrift AP, et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology. 2016;45:884-895.
52. Carreras-Torres R, Johansson M, Haycock PC, et al. Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PLOS ONE. 2017;12:e0177875.
53. Noyce AJ, Kia DA, Hemani G, et al. Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLOS Medicine. 2017;14:e1002314.
54. Guo Y, Warren Andersen S, Shu X-0, et al. Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLOS Medicine. 2016;13:e1002105.
55. Larsson SC, Scott RA, Traylor M, et al. Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes. Neurology. 2017;89:454-460.
56. Benn M, Tybjærg-Hansen A, Davey Smith G and Nordestgaard BG. High body mass index and cancer risk—a Mendelian randomisation study. European Journal of Epidemiology. 2016;31:879-892.
57. Collins R. What makes UK Biobank special? The Lancet. 2012;379:1173-1174.
58. Bycroft C, Freeman C, Petkova D, et al. Genome-wide genetic data on $\sim 500,000$ UK Biobank participants. bioRxiv. 2017.
59. Allen NE, Sudlow C, Peakman T and Collins R. UK Biobank Data: Come and Get It. Science Translational Medicine. 2014;6:224ed4.
60. Tyrrell J, Jones SE, Beaumont R, et al. Height, body mass index, and socioeconomic status: mendelian randomisation study in UK Biobank. BMJ. 2016;352.
61. Mitchell R, Hemani G, Dudding T, Paternoster L. UK Biobank Genetic Data: MRC-IEU Quality Control, Version 1. 2017.
62. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197-206.
63. Thomas DC, Lawlor DA and Thompson JR. Re: Estimation of Bias in Nongenetic Observational Studies Using "Mendelian Triangulation" by Bautista et al. Annals of Epidemiology. 2007;17:511-513.
64. Burgess S, Davies NM, Thompson SG and EPIC-InterAct Consortium. Instrumental variable analysis with a nonlinear exposure-outcome relationship. Epidemiology. 2014;25:877-885.
65. Staley JR and Burgess S. Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genet Epidemiol. 2017;41:341-352.
66. Bowden J, Davey Smith G and Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International Journal of Epidemiology. 2015.
67. Bowden J, Davey Smith G, Haycock PC and Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology. 2016;40:304-314.
68. Hartwig FP, Davey Smith G and Bowden J. Robust Inference In Two-Sample Mendelian Randomisation Via The Zero Modal Pleiotropy Assumption. bioRxiv. 2017.
69. Bowden J, Burgess S and Davey Smith G. Response to Hartwig and Davies. International Journal of Epidemiology. 2016;45:1679-1680.
70. Hartwig FP and Davies NM. Why internal weights should be avoided (not only) in MR-Egger regression. International Journal of Epidemiology. 2016;45:1676-1678.
71. Manson JE, Stampfer MJ, Hennekens CH and Willett WC. Body weight and longevity: A reassessment. JAMA. 1987;257:353-358.
72. Manson JE, Willett WC, Stampfer MJ, et al. Body Weight and Mortality among Women. New England Journal of Medicine. 1995;333:677-685.
73. Roh L, Braun J, Chiolero A, Bopp M, Rohrmann S and Faeh D. Mortality risk associated with underweight: a census-linked cohort of 31,578 individuals with up to 32 years of follow-up. BMC Public Health. 2014;14:371.
74. Munafo MR, Tilling K, Taylor AE, Evans DM and Davey Smith G. Collider Scope: How selection bias can induce spurious associations. bioRxiv. 2016; doi: https://doi.org/10.1101/079707.

Table 1. Descriptive statistics for UK Biobank participants of White British Ancestry included in the main analyses

| Variable | N | Mean (SD) or percentage |
| :---: | :---: | :---: |
| Age (years) at initial assessment | 335,308 | 56.87 (8.00) |
| Sex (\% of males) | 335,308 | 46.22 |
| Body mass index ( $\mathrm{kg} / \mathrm{m}^{2}$ ) | 335,308 | 27.38 (4.74) |
| Smoking status | 334,142 |  |
| Never | 183,170 | 54.82 |
| Former | 117,838 | 35.26 |
| Current | 33,134 | 9.92 |
| Alcohol drinker status | 335,074 |  |
| Never | 10,311 | 3.08 |
| Former | 11,368 | 3.39 |
| Current | 313,395 | 93.53 |
| Highest qualifications | 275,544 |  |
| College or University degree | 106,280 | 38.57 |
| A-levels | 38,271 | 13.89 |
| O-levels | 73,770 | 26.77 |
| CSEs | 18,016 | 6.54 |
| NVQ/HND/HNC | 22,012 | 7.99 |
| Other professional qualifications | 17,195 | 6.24 |
| Current employment status | 332,835 |  |
| In paid employment or self-employed | 190,085 | 57.11 |
| Retired | 117,615 | 35.34 |
| Looking after home/family | 8,690 | 2.61 |
| Unable to work due to sickness/disability | 9,982 | 3.00 |
| Unemployed | 4,436 | 1.33 |
| Doing unpaid or voluntary work | 1,404 | 0.42 |
| Full or part-time student | 623 | 0.19 |
| Days/week spent doing vigorous physical activity | 319.813 | 1.82 (1.94) |
| Genotyping chip ${ }^{2}$ | 335,308 | 9.24 |
| Age at death (years) | 9,570 | 65.66 (6.88) |
| Date of death ${ }^{1}$ |  | $\begin{gathered} 06 / 02 / 2013 \\ (07 / 07 / 2007-16 / 02 / 2016) \\ \hline \end{gathered}$ |

CSE = certificate of secondary education; HNC = higher national certificate; HND = higher national diploma;
NVQ = national vocational qualification; $S D=$ standard deviation
${ }^{1}$ Recorded as the mean (minimum and maximum) date of death
${ }^{2}$ UK BiLEVE participants genotyped on the Affymetrix Axiom Array

Table 2. Observational and MR analyses of all-cause and cause-specific mortality by BMI in UK Biobank participants of White British ancestry

| Cause of death | N1 | Observational |  |  |  | MR-analyses |  | DWH ${ }^{4}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Unadjusted |  | Adjusted ${ }^{3}$ |  |  |  |  |
|  |  | HR (95\% CI) ${ }^{2}$ | $P$-value | HR (95\% CI) ${ }^{2}$ | $P$-value | HR (95\% CI) ${ }^{\mathbf{2}}$ | $P$-value |  |
| All-cause | 9570 | 1.02 (1.02, 1.03) | $2.76 \times 10^{-27}$ | 1.02 (1.01, 1.02) | $9.72 \times 10^{-11}$ | 1.02 (0.97, 1.06) | 0.45 | 0.95 |
| Cardiovascular disease | 1967 | 1.07 (1.06, 1.08) | $8.91 \times 10^{-60}$ | 1.07 (1.06, 1.08) | $2.12 \times 10^{-34}$ | 1.12 (1.02, 1.23) | 0.02 | 0.38 |
| Coronary heart disease | 1087 | 1.08 (1.06, 1.09) | $5.61 \times 10^{-36}$ | 1.08 (1.06, 1.09) | $2.22 \times 10^{-22}$ | 1.19 (1.05, 1.35) | 0.01 | 0.13 |
| Stroke | 346 | 1.02 (0.99, 1.04) | 0.18 | 1.01 (0.98, 1.04) | 0.60 | 0.98 (0.78, 1.24) | 0.89 | 0.83 |
| Aortic aneurysm | 109 | 1.03 (0.99, 1.07) | 0.18 | 1.02 (0.97, 1.07) | 0.50 | 0.86 (0.59, 1.27) | 0.46 | 0.40 |
| Other cardiovascular disease | 425 | 1.11 (1.09, 1.13) | $2.07 \times 10^{-40}$ | 1.10 (1.08, 1.13) | $6.66 \times 10^{-22}$ | 1.13 (0.93, 1.38) | 0.22 | 0.81 |
| Respiratory diseases | 532 | 0.99 (0.97, 1.01) | 0.27 | 0.98 (0.95, 1.00) | 0.09 | 0.88 (0.72, 1.07) | 0.21 | 0.30 |
| Cancer | 5613 | 1.01 (1.01, 1.02) | $6.13 \times 10^{-05}$ | 1.01 (1.00, 1.01) | 0.03 | $0.98(0.93,1.03)$ | 0.42 | 0.27 |
| Lung cancer | 993 | 0.98 (0.97, 1.00) | 0.03 | 0.97 (0.95, 0.99) | 0.004 | 0.97 (0.84, 1.11) | 0.63 | 0.93 |
| Colorectal cancer | 552 | 1.01 (0.99, 1.03) | 0.29 | 1.01 (0.99, 1.03) | 0.34 | 1.10 (0.93, 1.29) | 0.25 | 0.31 |
| Pancreatic cancer | 388 | $1.01(0.99,1.03)$ | 0.53 | $1.01(0.99,1.04)$ | 0.39 | 1.02 (0.84, 1.25) | 0.83 | 0.92 |
| Stomach cancer | 144 | 1.06 (1.02, 1.09) | 0.001 | 1.04 (1.00, 1.09) | 0.06 | 1.30 (0.91, 1.86) | 0.16 | 0.23 |
| Oesophageal cancer | 283 | 1.03 (1.01, 1.06) | 0.01 | 1.03 (0.99, 1.06) | 0.11 | 1.08 (0.84, 1.38) | 0.55 | 0.70 |
| Malignant melanoma | 119 | 1.00 (0.96, 1.04) | 0.90 | 0.97 (0.92, 1.02) | 0.23 | 1.06 (0.76, 1.50) | 0.72 | 0.59 |
| Kidney cancer | 181 | $1.08(1.05,1.11)$ | $7.45 \times 10^{-09}$ | 1.07 (1.03, 1.11) | $1.40 \times 10^{-04}$ | 0.96 (0.70, 1.32) | 0.81 | 0.50 |
| Bladder cancer | 101 | $1.01(0.97,1.06)$ | 0.62 | 0.96 (0.90, 1.02) | 0.17 | $0.84(0.56,1.26)$ | 0.40 | 0.53 |
| Brain cancer | 280 | 1.01 (0.98, 1.03) | 0.57 | 1.01 (0.98, 1.04) | 0.64 | 1.01 (0.80, 1.27) | 0.95 | 0.999 |
| Liver cancer | 169 | 1.07 (1.04, 1.10) | $1.76 \times 10^{-06}$ | 1.05 (1.01, 1.09) | 0.01 | 0.95 (0.69, 1.30) | 0.74 | 0.52 |
| Lymphatic cancer | 528 | 1.00 (0.98, 1.02) | 0.75 | 0.99 (0.97, 1.02) | 0.60 | 1.03 (0.86, 1.22) | 0.76 | 0.71 |
| Other cancer | 755 | 1.00 (0.98, 1.01) | 0.66 | 1.00 (0.98, 1.02) | 0.84 | 0.95 (0.82, 1.10) | 0.52 | 0.54 |
| External causes | 306 | 0.98 (0.96, 1.01) | 0.14 | 0.96 (0.94, 0.99) | 0.02 | 1.35 (1.09, 1.67) | 0.01 | 0.002 |
| Other | 1099 | 1.01 (1.00, 1.02) | 0.08 | 1.00 (0.99, 1.02) | 0.62 | 1.00 (0.88, 1.14) | 0.97 | 0.98 |

$B M I=$ body mass index; CI = confidence interval; DWH = Durbin-Wu-Hausman; HR = hazard ratio; MR = Mendelian randomization
${ }^{1}$ Number of deaths from all causes or cause-specific mortality
${ }^{2}$ Adjusted for secular trends (date of birth) and sex, estimates represent HR with each unit increase in BMI (kg/m²)
${ }^{3}$ Additionally adjusted for highest household occupation, education, smoking status, alcohol intake, physical activity and the first ten genetic PCs
${ }^{4} P$-value for comparing estimates derived from observational and MR analyses using a simplification of the matrix method for DWH test statistic (see Supporting Methods)

Table 3. Observational and MR analyses of all-cause and cause-specific mortality by BMI in males of White British ancestry

| Cause of death | N1 | Observational |  |  |  | MR-analyses |  | DWH ${ }^{4}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Unadjusted |  | Adjusted ${ }^{3}$ |  |  |  |  |
|  |  | HR (95\% CI) ${ }^{2}$ | $P$-value | HR (95\% CI) ${ }^{2}$ | $P$-value | HR (95\% CI) ${ }^{\mathbf{2}}$ | $P$-value |  |
| All-cause | 5882 | 1.03 (1.02, 1.03) | $4.00 \times 10^{-18}$ | 1.02 (1.01, 1.03) | $2.65 \times 10^{-07}$ | 1.03 (0.97, 1.09) | 0.39 | 0.84 |
| Cardiovascular disease | 1467 | 1.08 (1.07, 1.09) | $1.23 \times 10^{-48}$ | 1.08 (1.06, 1.09) | $1.12 \times 10^{-27}$ | 1.10 (0.98, 1.24) | 0.10 | 0.67 |
| Coronary heart disease | 906 | 1.08 (1.07, 1.09) | $8.84 \times 10^{-32}$ | 1.08 (1.06, 1.09) | $8.61 \times 10^{-18}$ | 1.20 (1.04, 1.40) | 0.02 | 0.14 |
| Stroke | 194 | 1.03 (0.99, 1.06) | 0.10 | $1.02(0.98,1.07)$ | 0.27 | 0.90 (0.64, 1.26) | 0.52 | 0.43 |
| Aortic aneurysm | 83 | 1.04 (0.99, 1.09) | 0.14 | 1.03 (0.96, 1.09) | 0.41 | 0.82 (0.52, 1.31) | 0.40 | 0.34 |
| Other cardiovascular disease | 284 | 1.11 (1.09, 1.14) | $9.96 \times 10^{-25}$ | 1.11 (1.08, 1.14) | $9.33 \times 10^{-15}$ | 1.06 (0.82, 1.37) | 0.66 | 0.72 |
| Respiratory diseases | 361 | $0.94(0.91,0.97)$ | $1.08 \times 10^{-05}$ | 0.91 (0.88, 0.95) | $2.28 \times 10^{-06}$ | $0.84(0.65,1.09)$ | 0.19 | 0.53 |
| Cancer | 3113 | 1.01 (1.00, 1.02) | 0.002 | 1.01 (1.00, 1.02) | 0.06 | 1.00 (0.92, 1.08) | 0.95 | 0.76 |
| Lung cancer | 571 | 0.96 (0.94, 0.98) | $2.28 \times 10^{-04}$ | 0.94 (0.91, 0.97) | $3.54 \times 10^{-05}$ | 0.96 (0.79, 1.18) | 0.70 | 0.82 |
| Prostate cancer | 308 | 1.03 (1.01, 1.06) | 0.01 | 1.05 (1.02, 1.08) | 0.003 | 0.73 (0.57, 0.93) | 0.01 | 0.004 |
| Colorectal cancer | 329 | 1.03 (1.00, 1.05) | 0.04 | $1.02(0.99,1.05)$ | 0.28 | 1.17 (0.93, 1.47) | 0.18 | 0.23 |
| Pancreatic cancer | 201 | 1.01 (0.97, 1.04) | 0.76 | 1.00 (0.96, 1.04) | 0.98 | 1.04 (0.77, 1.41) | 0.80 | 0.79 |
| Stomach cancer | 105 | 1.07 (1.03, 1.11) | $5.08 \times 10^{-04}$ | 1.06 (1.01, 1.12) | 0.03 | 1.32 (0.84, 2.08) | 0.23 | 0.35 |
| Oesophageal cancer | 226 | 1.06 (1.03, 1.09) | $1.06 \times 10^{-04}$ | 1.07 (1.04, 1.11) | $8.50 \times 10^{-05}$ | 1.20 (0.88, 1.62) | 0.25 | 0.48 |
| Malignant melanoma | 78 | $0.99(0.94,1.05)$ | 0.85 | $0.97(0.91,1.04)$ | 0.40 | 0.91 (0.57, 1.46) | 0.71 | 0.80 |
| Kidney cancer | 137 | 1.09 (1.05, 1.12) | $8.27 \times 10^{-07}$ | 1.08 (1.03, 1.13) | $5.58 \times 10^{-04}$ | $1.08(0.73,1.60)$ | 0.70 | 0.998 |
| Bladder cancer | 78 | 0.98 (0.93, 1.04) | 0.58 | 0.93 (0.87, 1.00) | 0.06 | 0.90 (0.55, 1.45) | 0.66 | 0.88 |
| Brain cancer | 169 | $1.01(0.97,1.05)$ | 0.59 | 0.98 (0.94, 1.03) | 0.44 | $1.29(0.93,1.79)$ | 0.12 | 0.10 |
| Liver cancer | 100 | 1.11 (1.07, 1.15) | $3.18 \times 10^{-08}$ | 1.08 (1.03, 1.13) | 0.003 | 0.81 (0.52, 1.25) | 0.34 | 0.20 |
| Lymphatic cancer | 329 | 1.00 (0.97, 1.03) | 0.91 | $1.01(0.98,1.04)$ | 0.59 | $1.04(0.82,1.32)$ | 0.74 | 0.79 |
| Other cancer | 460 | $0.99(0.96,1.01)$ | 0.22 | 1.00 (0.97, 1.03) | 0.88 | 0.90 (0.74, 1.11) | 0.33 | 0.31 |
| External causes | 206 | 0.97 (0.94, 1.01) | 0.12 | 0.97 (0.93, 1.01) | 0.11 | 1.25 (0.94, 1.67) | 0.13 | 0.08 |
| Other | 696 | 1.00 (0.99, 1.02) | 0.65 | 0.99 (0.97, 1.01) | 0.38 | 1.00 (0.84, 1.18) | 0.97 | 0.94 |

$B M I=$ body mass index; CI = confidence interval; DWH = Durbin-Wu-Hausman; HR = hazard ratio; MR = Mendelian randomization
${ }^{1}$ Number of deaths from all causes or cause-specific mortality
${ }^{2}$ Adjusted for secular trends (date of birth), estimates represent HR with each unit increase in BMI ( $\mathrm{kg} / \mathrm{m}^{2}$ )
${ }^{3}$ Additionally adjusted for highest household occupation, education, smoking status, alcohol intake, physical activity and the first ten genetic PCs
${ }^{4} P$-value for comparing estimates derived from observational and MR analyses using a simplification of the matrix method for DWH test statistic (see Supporting Methods)

Table 4. Observational and MR analyses of all-cause and cause-specific mortality by BMI in females of White British ancestry

| Cause of death | N ${ }^{1}$ | Observational |  |  |  | MR-analyses |  | DWH ${ }^{4}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Unadjusted |  | Adjusted ${ }^{3}$ |  |  |  |  |
|  |  | HR (95\% CI) ${ }^{2}$ | $P$-value | HR (95\% CI) ${ }^{2}$ | $P$-value | HR (95\% CI) ${ }^{2}$ | $P$-value |  |
| All-cause | 3688 | 1.02 (1.01, 1.03) | $1.84 \times 10^{-11}$ | 1.02 (1.01, 1.02) | $3.70 \times 10^{-05}$ | 1.00 (0.94, 1.07) | 0.90 | 0.71 |
| Cardiovascular disease | 500 | 1.06 (1.04, 1.08) | $6.64 \times 10^{-14}$ | 1.06 (1.04, 1.08) | $1.86 \times 10^{-08}$ | 1.18 (0.98, 1.43) | 0.08 | 0.26 |
| Coronary heart disease | 181 | 1.06 (1.03, 1.09) | $5.05 \times 10^{-06}$ | 1.08 (1.04, 1.11) | $9.21 \times 10^{-06}$ | 1.20 (0.86, 1.67) | 0.29 | 0.54 |
| Stroke | 152 | 1.01 (0.97, 1.04) | 0.75 | 1.00 (0.95, 1.04) | 0.84 | 1.10 (0.78, 1.54) | 0.58 | 0.56 |
| Other cardiovascular disease | 141 | 1.11 (1.08, 1.14) | 0 | 1.10 (1.06, 1.13) | $8.74 \times 10^{-09}$ | 1.30 (0.93, 1.82) | 0.13 | 0.33 |
| Respiratory diseases | 171 | 1.05 (1.02, 1.08) | $3.94 \times 10^{-04}$ | 1.06 (1.02, 1.09) | 0.002 | 0.96 (0.68, 1.34) | 0.80 | 0.56 |
| Cancer | 2500 | 1.01 (1.00, 1.02) | 0.01 | 1.01 (1.00, 1.02) | 0.20 | 0.96 (0.89, 1.03) | 0.25 | 0.19 |
| Lung cancer | 422 | $1.01(0.99,1.03)$ | 0.53 | 1.00 (0.97, 1.03) | 0.99 | 0.97 (0.79, 1.19) | 0.78 | 0.78 |
| Breast cancer | 468 | 1.02 (1.00, 1.03) | 0.05 | 1.02 (1.00, 1.04) | 0.13 | 0.87 (0.73, 1.02) | 0.09 | 0.06 |
| Pre-menopausal | 48 | 1.00 (0.95, 1.06) | 0.94 | $1.01(0.95,1.06)$ | 0.84 | 0.81 (0.50, 1.30) | 0.38 | 0.37 |
| Post-menopausal | 420 | 1.02 (1.00, 1.04) | 0.04 | 1.02 (1.00, 1.04) | 0.13 | 0.87 (0.73, 1.04) | 0.14 | 0.09 |
| Colorectal cancer | 223 | 0.99 (0.97, 1.02) | 0.59 | 1.01 (0.98, 1.04) | 0.72 | 1.02 (0.81, 1.30) | 0.84 | 0.87 |
| Pancreatic cancer | 187 | $1.01(0.98,1.04)$ | 0.57 | $1.02(0.98,1.05)$ | 0.29 | 1.01 (0.76, 1.33) | 0.97 | 0.93 |
| Ovarian cancer | 211 | 1.00 (0.97, 1.02) | 0.76 | 1.00 (0.96, 1.03) | 0.79 | 1.13 (0.88, 1.45) | 0.33 | 0.31 |
| Endometrial cancer | 50 | 1.10 (1.06, 1.15) | $3.29 \times 10^{-06}$ | 1.12 (1.07, 1.18) | $1.29 \times 10^{-05}$ | 0.71 (0.41, 1.23) | 0.23 | 0.10 |
| Oesophageal cancer | 57 | 0.95 (0.90, 1.01) | 0.10 | 0.87 (0.80, 0.95) | 0.001 | 0.81 (0.50, 1.31) | 0.38 | 0.75 |
| Malignant melanoma | 41 | 1.00 (0.94, 1.06) | 0.95 | 0.97 (0.90, 1.04) | 0.39 | 1.33 (0.78, 2.27) | 0.29 | 0.24 |
| Kidney cancer | 44 | 1.08 (1.03, 1.13) | 0.002 | 1.06 (0.99, 1.13) | 0.07 | 0.71 (0.39, 1.30) | 0.27 | 0.19 |
| Brain cancer | 111 | 1.00 (0.97, 1.04) | 0.80 | 1.03 (0.99, 1.07) | 0.19 | 0.75 (0.54, 1.05) | 0.09 | 0.06 |
| Liver cancer | 69 | 1.03 (0.99, 1.08) | 0.18 | 1.03 (0.97, 1.09) | 0.35 | 1.17 (0.73, 1.86) | 0.51 | 0.58 |
| Lymphatic cancer | 199 | 1.00 (0.97, 1.02) | 0.76 | 0.98 (0.94, 1.01) | 0.22 | $1.01(0.77,1.32)$ | 0.94 | 0.80 |
| Other cancer | 295 | $1.01(0.98,1.03)$ | 0.52 | $0.99(0.96,1.02)$ | 0.60 | 1.02 (0.82, 1.27) | 0.87 | 0.81 |
| External causes | 100 | $0.99(0.95,1.03)$ | 0.72 | 0.96 (0.92, 1.01) | 0.10 | 1.56 (1.10, 2.20) | 0.01 | 0.01 |
| Other | 403 | 1.02 (1.00, 1.04) | 0.04 | 1.02 (1.00, 1.04) | 0.09 | 1.01 (0.83, 1.23) | 0.92 | 0.92 |

BMI = body mass index; CI = confidence interval; DWH = Durbin-Wu-Hausman; HR = hazard ratio; MR = Mendelian randomization
${ }^{1}$ Number of deaths from all causes or cause-specific mortality
${ }^{2}$ Adjusted for secular trends (date of birth), estimates represent HR with each unit increase in BMI ( $\mathrm{kg} / \mathrm{m}^{2}$ )
${ }^{3}$ Additionally adjusted for highest household occupation, education, smoking status, alcohol intake, physical activity and the first ten genetic PCs
${ }^{4} P$-value for comparing estimates derived from observational and MR analyses using a simplification of the matrix method for DWH test statistic (see Supporting Methods)

Table 5. Association between weighted GRS (comprising 77 SNPs) and BMI in UK Biobank participants of White British ancestry

| Sample | $\mathbf{N}$ | Effect estimate <br> $\mathbf{( 9 5 \% \mathbf { C I } \mathbf { 1 } ^ { \mathbf { 1 } }}$ | $\boldsymbol{P}$-value | $\mathbf{R}^{\mathbf{2}} \mathbf{( \% )}^{\mathbf{2}}$ |
| :--- | :---: | :---: | :---: | :---: |
| Whole sample | 335,308 | $0.11(0.11,0.11)$ | $<1.20 \times 10^{-307}$ | 1.81 |
| Males | 154,967 | $0.10(0.10,0.11)$ | $<1.20 \times 10^{-307}$ | 2.05 |
| Females | 180,341 | $0.12(0.11,0.12)$ | $<1.20 \times 10^{-307}$ | 1.70 |

$B M I=$ body mass index; CI = confidence interval; GRS = genetic risk score; $S N P=$ single nucleotide polymorphism
${ }^{1}$ Effect estimate (and corresponding P-value) represents the change in BMI ( $\mathrm{kg} / \mathrm{m}^{2}$ ) per BMI-increasing allele in individuals of White British ancestry adjusted for the first ten genetic PCs
${ }^{2}$ Variance explained

## Figure Legends

Figure 1. Flow-chart of those included in main analyses
Figure 2. Assessment of linearity in associations of the GRS (comprising 77 SNPs) and all-cause mortality in the UK Biobank sample of White British ancestry

Figure 3. Assessment of linearity in associations of BMI and all-cause mortality in the UK Biobank sample of White British ancestry using BMI (A) and instrument-free BMI (B)

Figure 1. Flow-chart of those included in main analyses


BMI = body mass index
${ }^{1}$ Of those with valid BMI, genetic and survival data, 335,308 were of White British ancestry
${ }^{2}$ Of those who had died by the $16{ }^{\text {th }}$ February 2016, 9,570 were of White British ancestry

Figure 2. Assessment of linearity in associations of the GRS (comprising 77 SNPs, right) and all-cause mortality in the UK Biobank sample of White British ancestry.


Association between the GRS (comprising 77 SNPs) and all-cause mortality, adjusted for the same variables as with BMI (Figure 2). Linearity tests were conducted after removing data below/above the 1st/99th percentile of BMI, respectively, due to the scarcity of data towards the tails of the BMI distribution. Hazard ratios (HRs) were calculated relative to the mean GRS value with 1000 bootstrap resamples to obtain confidence intervals (CIs). The black lines represent the fitted HRs from cubic spline models (with the mean value of the GRS as the reference).

Figure 3. Assessment of linearity in associations of BMI and all-cause mortality in the UK Biobank sample of White British ancestry using BMI (A) and instrumentfree BMI (B).
(A)

(B)


A: Fully-adjusted observational associations between BMI and all-cause mortality obtained using conventional Cox regression.
B: An approximate MR analogue of the instrument-free exposure (set at the $5^{\text {th }}, 10^{\text {th }}, 25^{\text {th }}, 50^{\text {th }}, 75^{\text {th }}$ and $85^{\text {th }}$ percentile). These localised average causal effects were then joined together and plotted against the corresponding percentiles of the original exposure.
Linearity tests were conducted after removing data below/above the 1st/99th percentile, respectively, due to the scarcity of data towards the tails of the BMI distribution. Hazard ratios (HRs) were calculated relative to the mean BMI ( $27 \mathrm{~kg} / \mathrm{m}^{2}$ ), with 1000 bootstrap resamples to obtain confidence intervals (CIs). The darker lines represent the fitted HRs from cubic spline models (with mean BMI as the reference).

